An example of the former is the monoclonal antibody daratumumab, which targets CD38 on the surface of myeloma plasma cells, whilst a precision therapeutic could be the application of venetoclax in those myeloma patients whose plasma cells harbour t(11;14), which upregulates bcl-2, the target of venetoclax [6,7]. This evidence concerns the gene BCL2 and plasma cell myeloma.